Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Boston Therapeutics Inc (OTC: BTHE).

Full DD Report for BTHE

You must become a subscriber to view this report.


Recent News from (OTC: BTHE)

Boston Therapeutics Phase IIa Study Results Accepted for Publication
LAWRENCE, Mass., Aug. 24, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is pleased to announce the acceptance of the Phase IIa proof of concept study evaluating the efficacy and safety of BTI320 on post-prandial hyperglycemia in Chinese subjects with pre-diabetes for publication...
Source: GlobeNewswire
Date: August, 24 2018 09:30
Boston Therapeutics to launch social commerce channel for Sugardown® in China
LAWRENCE, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (“ BTI ”) (OTCQB:BTHE), a BioPharmaceutical leader in the design, development and commercialization of innovative therapeutics for sugar management, diabetes and related complications, announces the la...
Source: GlobeNewswire
Date: August, 09 2018 11:52
Boston Therapeutics Introduces Sugardown® to the US under kathy Ireland® Health & Wellness
LAWRENCE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “ Company ” or “ BTI ”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for metabolism and sugar control for conditions such as pre-...
Source: GlobeNewswire
Date: June, 27 2018 12:52
Level Brands signs deal with Boston Therapeutics
Level Brands (NYSEMKT: LEVB ) announced a seven-year licensing agreement with Boston Therapeutics, Inc. ( OTCQB:BTHE ), licensing the kathy Ireland Health & Wellness brand to market its popular diabetes supplement, Sugardown. More news on: Level Brands, Inc., Boston Therapeutics Inc, C...
Source: SeekingAlpha
Date: June, 27 2018 07:11
Boston Therapeutics Initiates New Clinical Study of BTI-320
LAWRENCE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “ Company ” or “ BTI ”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for diabetes and related complications, announces the start o...
Source: GlobeNewswire
Date: May, 22 2018 12:58
Boston Therapeutics Phase I Study Results Accepted for Publication
LAWRENCE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is pleased to announce the acceptance of the Phase I proof of concept study of the pharmacology of BTI-320 prior to high glycemic meals for publication in the Journal of Clinical Pharmacology in Drug Developm...
Source: GlobeNewswire
Date: May, 10 2018 13:04
Boston Therapeutics Corporate Call Transcript Posted
LAWRENCE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “ Company ” or “ BTI ”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for the potential treatment of diabetes and related complic...
Source: GlobeNewswire
Date: April, 27 2018 12:01
Boston Therapeutics to Hold Business Update Conference Call Wednesday, April 18, 2018 at 5:00 p.m. ET
LAWRENCE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “ Company ” or “ BTI ”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for the potential treatment of diabetes and related complic...
Source: GlobeNewswire
Date: April, 16 2018 11:35
Boston Therapeutics Announces Letter of Intent to Acquire Pennsylvania-based Medical Technology Associates II (MTA2)
LAWRENCE, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “ Company ” or “ BTI ”) (OTCQB:BTHE) is pleased to announce that it has entered into a non-binding letter of intent dated April 11, 2018 (the “ Letter of Intent ”) wit...
Source: GlobeNewswire
Date: April, 12 2018 09:35
Boston Therapeutics Awarded Key European Patent
LAWRENCE, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics (the “ Company ” or “ BTI ”) (OTCQB:BTHE) is pleased to announce that it has won a patent position argued with the European Patent and Trademark Office this week.  The patent has claims ...
Source: GlobeNewswire
Date: April, 06 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.0450.0450.0450.04541,500
2018-12-130.0370.050.050.0371,500
2018-12-120.0380.0420.0420.03830,000
2018-12-110.0370.050.050.03768,000
2018-12-100.0410.0410.0410.04135,099

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1415,00041,50036.1446Short
2018-12-1210,00030,00033.3333Cover
2018-12-112,00068,0002.9412Cover
2018-12-0731,30042,85073.0455Short
2018-12-0413,50026,39951.1383Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BTHE.


About Boston Therapeutics Inc (OTC: BTHE)

Logo for Boston Therapeutics Inc (OTC: BTHE)

Boston Therapeutics, Inc. OTCQB: BTHE , headquartered in Lawrence, MA, is a leader in the field of designing drugs using complex carbohydrates. The Company s product pipeline is focused on developing and commercializing therapeutic molecules for diabetes, including: BTI , a non systemic chewable compound designed to reduce post meal glucose elevation IPOXYN, an injectable anti necrosis drug specifically designed to treat lower limb ischemia and SUGARDOWN R , an OTC dietary supplement designed to lower post meal sugar spike. More information on BTHE is available at www.bostonti.com.

 

Contact Information

 

 

Current Management

  • Carl Rausch / CEO
  • Loraine V. Upham / COO
  • Stephen Spanos / Consultant
  • Conroy Cheng /
  • S. Colin Neill /
  • Carl Rausch /

Current Share Structure

  • Market Cap: $4,230,601 - 03/15/2018
  • Authorized: 200,000,000 - 03/07/2017
  • Issue and Outstanding: 60,437,163 - 11/13/2017
  • Float: 19,337,223 - 10/23/2017

 


Recent Filings from (OTC: BTHE)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: April, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 27 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: February, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 12 2018
All other definitive information statements
Filing Type: DEF 14CFiling Source: edgar
Filing Date: February, 09 2018
Preliminary proxy statement containing all other information
Filing Type: PRE 14CFiling Source: edgar
Filing Date: January, 22 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 13 2017
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: November, 01 2017

 

 


Daily Technical Chart for (OTC: BTHE)

Daily Technical Chart for (OTC: BTHE)


Stay tuned for daily updates and more on (OTC: BTHE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BTHE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BTHE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BTHE and does not buy, sell, or trade any shares of BTHE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/